Pediatric Respiratory Syncytial Virus Rsv

Disclaimer: This information is intended for educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Clinicians must always exercise their independent medical judgment and consider individual patient circumstances when making healthcare decisions. Dosages and recommendations are subject to change based on evolving evidence and guidelines.

---

Overview

• Definition: Respiratory Syncytial Virus (RSV) is a common, highly contagious RNA virus that causes respiratory tract infections. In infants and young children, it is the most common cause of bronchiolitis (inflammation of the small airways in the lungs) and pneumonia.
• Epidemiology:
  • Prevalence: Nearly all children are infected with RSV by age 2 years. Re-infections are common throughout life, but subsequent infections are typically milder.
  • Seasonality: RSV infections occur annually, typically in fall, winter, and early spring in temperate climates. The exact timing and duration of the RSV season can vary by geography and year. In the Northern Hemisphere, activity usually peaks between December and February.
  • Burden: RSV causes millions of outpatient visits, hundreds of thousands of hospitalizations, and hundreds of deaths annually in the U.S. among children <5 years old. Infants under 6 months of age are at highest risk for severe disease and hospitalization.
  • Demographics: While RSV affects all children, certain populations are at higher risk for severe disease, including premature infants, infants with chronic lung disease (CLD) of prematurity, hemodynamically significant congenital heart disease (CHD), neuromuscular disorders, and immunocompromised children.
• Classification: RSV belongs to the Pneumoviridae family, genus Orthopneumovirus. It has two main antigenic subgroups, A and B, which co-circulate, with subgroup A typically predominating and often associated with more severe disease.

Pathophysiology

• Mechanism:
  • Infection: RSV is transmitted primarily via large respiratory droplets and direct contact with infected secretions. The virus enters the host through the conjunctiva or nasal mucosa.
  • Replication: It infects epithelial cells of the upper respiratory tract, then spreads to the lower respiratory tract, primarily affecting the bronchioles and small airways.
  • Cellular Damage: Viral replication leads to direct cytopathic effects on respiratory epithelial cells. Infected cells fuse to form syncytia (hence "syncytial virus"), contributing to widespread inflammation.
  • Immune Response: The host immune response (both innate and adaptive) contributes significantly to the pathology. Inflammation leads to edema, mucus production, and necrosis of epithelial cells, causing obstruction of small airways.
  • Airway Obstruction: Airway obstruction is due to a combination of epithelial cell death, subepithelial edema, mucus plugging, and peribronchiolar lymphocytic infiltration. This leads to air trapping (manifested as hyperinflation), atelectasis, and ventilation-perfusion mismatch, resulting in hypoxemia.
  • Bronchiolitis: In infants, their small airways are particularly susceptible to severe obstruction due to their narrow caliber, underdeveloped collateral ventilation, and immature immune responses.
• Risk Factors (for severe disease requiring hospitalization or intensive care):
  • Prematurity: Especially infants born before 37 weeks gestation, with risk inversely proportional to gestational age.
  • Chronic Lung Disease of Prematurity (CLD/BPD): Infants requiring oxygen or medical therapy for CLD.
  • Hemodynamically Significant Congenital Heart Disease (CHD): Cyanotic heart disease, congestive heart failure.
  • Immunodeficiency: Primary or secondary (e.g., chemotherapy, HIV, transplantation).
  • Neuromuscular Disease: Conditions that impair ability to clear secretions or protect airways (e.g., hypotonia, muscular dystrophy).
  • Other chronic conditions: Cystic fibrosis, Down syndrome, severe pulmonary disorders.
  • Environmental Factors: Exposure to tobacco smoke, crowded living conditions, older siblings in school/daycare.
  • Age: Infants <6 months are at highest risk for severe disease.
  • Breastfeeding status: Lack of breastfeeding may increase risk.
• Protective Factors:
  • Maternal Antibodies: Transplacental antibodies offer some protection to neonates, but this wanes rapidly.
  • Breastfeeding: Provides passive antibodies and other immune factors.
  • Monoclonal Antibody Prophylaxis: Nirsevimab or Palivizumab (for specific high-risk populations).
  • Good Hygiene: Handwashing, avoiding close contact with sick individuals.

Clinical Presentation

Signs and Symptoms

RSV infection typically begins with upper respiratory tract symptoms, progressing to lower respiratory tract involvement in many infants. - Cardinal Features (especially in bronchiolitis): * Cough: Persistent, often paroxysmal. * Tachypnea: Rapid breathing. * Wheezing: High-pitched whistling sound during breathing, particularly expiration. * Retractions: Supraclavicular, intercostal, subcostal indrawing of the chest wall. * Nasal congestion/rhinorrhea: Profuse clear nasal discharge. * Fever: Low-grade to moderate (often <39°C), though can be absent, especially in very young infants. * Irritability/Decreased feeding: Due to respiratory distress and nasal congestion. - Early Signs (typically days 1-3 of illness): * Rhinorrhea (often profuse) * Sneezing * Mild cough * Low-grade fever * Decreased appetite - Advanced Signs (typically days 3-5, peak severity): * Increased work of breathing: Marked tachypnea, prominent retractions, nasal flaring. * Persistent wheezing, sometimes stridor. * Cyanosis (circumoral or generalized), indicates significant hypoxemia. * Apnea (especially in infants <2-3 months, premature infants). * Poor feeding, signs of dehydration (decreased wet diapers, sunken fontanelle). * Lethargy, decreased level of consciousness. * Grunting. - Atypical Presentations: * Neonates/Very Young Infants: May present with isolated apnea, poor feeding, irritability, or lethargy without significant respiratory symptoms (wheezing may be absent). Fever may be absent or low-grade. * Older Children/Adults: Typically presents as a common cold, but can cause bronchitis or pneumonia, especially in immunocompromised or elderly individuals.

Physical Examination

• Inspection:
  • General: Child appears irritable, anxious, or lethargic depending on severity. Check for signs of dehydration.
  • Respiratory Effort: Observe for tachypnea (respiratory rate often >60 breaths/min in infants), nasal flaring, head bobbing (severe distress), grunting, retractions (intercostal, subcostal, suprasternal, supraclavicular), accessory muscle use.
  • Skin/Mucous Membranes: Pallor, circumoral or generalized cyanosis (late sign).
  • Nose: Profuse clear nasal discharge.
• Palpation:
  • Thorax: Check for hyperinflation, which may manifest as a barrel chest appearance and downward displacement of the liver.
  • Skin turgor: Assess for dehydration.
• Auscultation:
  • Lungs: Diffuse expiratory and inspiratory wheezing, crackles (rales), rhonchi. May hear diminished breath sounds with severe air trapping or consolidation.
  • Heart: Tachycardia (due to fever, distress, dehydration).
  • Upper Airway: Rhonchi due to nasal/pharyngeal secretions.

Diagnostic Approach

History Taking

• Key Questions:
  • Onset and Progression: When did symptoms start? How have they evolved?
  • Type of Symptoms: Cough (character, frequency), nasal discharge, fever (peak temperature, duration), breathing difficulties (rate, effort, wheezing sounds).
  • Feeding: How much is the child eating/drinking? Any signs of dehydration (e.g., decreased wet diapers)?
  • Activity Level: Is the child lethargic or irritable?
  • Exposure: Any sick contacts at home, daycare, or school?
  • Risk Factors: Gestational age at birth, history of prematurity, chronic lung disease (e.g., BPD), congenital heart disease, immunodeficiency, neuromuscular disorders.
  • Current Medications/Prophylaxis: Has the child received Nirsevimab or Palivizumab?
  • Immunization Status: Especially for influenza and COVID-19.
• Red Flags:
  • Apnea episodes (especially recurrent or observed by parents).
  • Cyanosis (blue lips or skin).
  • Severe tachypnea (e.g., >70-80 breaths/min in an infant).
  • Significant retractions and increased work of breathing.
  • Lethargy or decreased level of consciousness.
  • Poor feeding and signs of dehydration.
  • Absence of crying or interaction.
  • Age <3 months with any respiratory symptoms.
  • Known high-risk underlying conditions.

Laboratory Tests

Laboratory testing is generally not required for diagnosis of RSV bronchiolitis in otherwise healthy children, as the diagnosis is primarily clinical. Testing may be considered for epidemiologic purposes, to guide infection control, or if the diagnosis is unclear. - First-Line: * Pulse Oximetry: Essential for assessing oxygen saturation and is a key indicator of severity. SpO2 <90-92% (depending on local guidelines) on room air typically indicates need for oxygen therapy and often hospitalization. - Confirmatory: * Rapid Antigen Detection Tests: Less sensitive (50-80%) and specific than PCR, but can provide quick results. Sensitivity varies with viral load. * Reverse Transcription Polymerase Chain Reaction (RT-PCR): Highly sensitive and specific (typically >95%) for RSV. Can detect low viral loads and differentiate between RSV and other respiratory viruses (e.g., influenza, metapneumovirus, rhinovirus) when part of a multiplex PCR panel. Sample collected via nasopharyngeal swab or aspirate. - Monitoring (in hospitalized patients): * Arterial Blood Gas (ABG): Rarely needed, may be considered in severe cases with suspected respiratory failure to assess for hypercapnia or significant acidosis. * Complete Blood Count (CBC): Typically not helpful for diagnosing RSV itself. May show mild lymphocytosis or normal white cell count. Not useful for differentiating viral from bacterial infection in RSV bronchiolitis unless there is strong suspicion for bacterial co-infection (e.g., secondary bacterial pneumonia, otitis media, UTI). * Blood Culture/Urine Culture: Only indicated if there is a strong suspicion of bacterial co-infection (e.g., prolonged fever without clear source, signs of sepsis). Studies show a low incidence of serious bacterial infection in RSV bronchiolitis.

Imaging

• Recommended:
  • Chest Radiograph (CXR): Generally not routinely recommended for typical bronchiolitis unless there is a strong suspicion of an alternative diagnosis (e.g., bacterial pneumonia, foreign body aspiration, congestive heart failure) or if the patient is severely ill and not responding to therapy.
  • Typical CXR findings in RSV bronchiolitis: Hyperinflation (flattened diaphragms, increased AP diameter), peribronchial cuffing, and atelectasis. Infiltrates or consolidation may be present in up to 25% of cases but do not typically indicate bacterial pneumonia without other clinical signs.
• Advanced:
  • High-Resolution Computed Tomography (HRCT): No role in routine diagnosis or management of acute RSV bronchiolitis. May be used in specific research settings or for evaluation of chronic lung disease following severe RSV.

Management

Key Principle: Management of RSV bronchiolitis is primarily supportive, focusing on maintaining adequate hydration, oxygenation, and respiratory support.

Acute Management

• Immediate (upon presentation to ED/clinic):
  • Rapid assessment of respiratory distress and oxygen saturation.
  • Ensure airway patency: Suctioning of nasal and oral secretions.
  • Initiate supplemental oxygen if SpO2 is <90-92% (target SpO2 90-92% or higher, depending on institutional guidelines and patient condition).
  • Assess hydration status and ability to feed.
• Stabilization (initial hospitalization/observation):
  • Oxygen Therapy: Nasal cannula is generally first-line. Consider high-flow nasal cannula (HFNC) for moderate to severe respiratory distress, as it can reduce work of breathing and improve oxygenation.
  • Hydration: Oral hydration is preferred if possible. If feeding is poor or respiratory effort is too high, administer intravenous (IV) fluids or nasogastric (NG) tube feeds to prevent dehydration and reduce aspiration risk. Monitor fluid input/output closely.
  • Airway Clearance: Nasal suctioning, especially before feeds and sleep. Bulb syringe or nasal aspirator for home use; hospital settings may use wall suction.
  • Monitoring: Continuous pulse oximetry, respiratory rate, heart rate, work of breathing, and temperature.
• Emergency (for severe cases or respiratory failure):
  • Non-invasive Ventilation (NIV): CPAP or BiPAP may be considered for patients with impending respiratory failure not responding to HFNC, though less commonly used for RSV bronchiolitis compared to HFNC.
  • Intubation and Mechanical Ventilation: Indicated for severe respiratory failure (e.g., persistent hypoxemia despite maximal oxygen, hypercapnia, severe apnea, exhaustion, deteriorating mental status).
  • Cardiac Monitoring: For patients with apnea or significant cardiac comorbidities.

Chronic Management

RSV is an acute illness, so there is no specific "chronic management" for the viral infection itself. However, monitoring and management for potential sequelae are important. - Pharmacological: * Bronchodilators (e.g., Albuterol): Not routinely recommended for RSV bronchiolitis. A trial may be considered for infants with a strong history of recurrent wheezing or asthma, or a family history of atopy, but should be discontinued if no clear clinical benefit is observed (i.e., improved work of breathing, reduced wheezing, increased SpO2). Evidence does not support routine use. * Corticosteroids (systemic or inhaled): Not recommended for routine use in RSV bronchiolitis. Studies show no significant benefit in reducing severity, duration of hospitalization, or length of illness. * Antivirals (e.g., Ribavirin): Not routinely recommended. Ribavirin has limited efficacy and significant toxicity, reserved only for very severe, life-threatening cases in highly immunocompromised patients (e.g., bone marrow transplant recipients), and requires careful consideration and consultation with infectious disease specialists. * Antibiotics: Not routinely recommended. RSV is a viral infection. Antibiotics should only be used if there is strong clinical evidence of a co-existing bacterial infection (e.g., secondary bacterial pneumonia, otitis media, UTI, sepsis). - Non-pharmacological: * Home monitoring: Parents should be educated on signs of worsening respiratory distress or dehydration. * Avoidance of irritants: Especially tobacco smoke. * Nasal saline and suctioning: For symptomatic relief of congestion. * Education: Parents should be advised about the typical course of illness and when to seek medical attention. - Monitoring: * Post-hospitalization: Follow-up with primary care provider to ensure complete recovery and address any persistent cough or feeding issues. * Long-term: Children who have severe RSV bronchiolitis, especially if hospitalized, may have an increased risk of recurrent wheezing or developing asthma in later childhood. Long-term pulmonary follow-up may be considered for those with persistent symptoms or significant comorbidities.

Treatment Algorithms

General Approach for Suspected RSV Bronchiolitis in Infants:

1. Assess Severity:

   • Mild: Good feeding, mild tachypnea, no/mild retractions, SpO2 >92% on room air.
   • Moderate: Reduced feeding, moderate tachypnea (e.g., 50-70 breaths/min), moderate retractions, SpO2 90-92% on room air.
   • Severe: Poor feeding/dehydration, marked tachypnea (>70 breaths/min), severe retractions/nasal flaring/grunting, SpO2 <90% on room air, lethargy, apnea, pallor/cyanosis.

2. Hospitalization Criteria:

   • SpO2 persistently <90-92% despite supplemental oxygen (or <90-92% on room air).
   • Significant respiratory distress (marked retractions, nasal flaring, grunting, tachypnea, apnea).
   • Poor feeding or signs of dehydration.
   • Lethargy, decreased activity, or altered mental status.
   • Age <3 months (lower threshold for admission due to risk of apnea).
   • Underlying risk factors (e.g., prematurity, CHD, CLD, immunodeficiency).
   • Inability to manage at home (e.g., lack of reliable caregivers, long travel distance to medical care).

3. First-Line Treatment (Supportive Care):

   • Oxygen Therapy: If SpO2 <90-92%. Start with nasal cannula.
   • Hydration: Oral preferred. IV or NG if inadequate oral intake.
   • Nasal Suctioning: PRN for secretions.
   • Observation: Monitor vital signs, oxygen saturation, work of breathing, and hydration.

4. Second-Line Treatment (Consider for Moderate-Severe or Worsening Cases):

   • High-Flow Nasal Cannula (HFNC): If increased work of breathing despite conventional oxygen. Provides positive airway pressure and washes out dead space.
   • Trial of Bronchodilator: Only if history of wheezing with good response, family history of asthma, or very specific circumstances. Discontinue if no objective improvement.
   • IV Fluids/NG Feeds: If oral intake remains poor or respiratory distress is high.

5. Refractory Cases (Indications for ICU/Higher Level of Care):

   • Impending Respiratory Failure: Worsening hypoxemia, increasing hypercapnia, exhaustion, persistent apnea, failure of HFNC.
   • Non-invasive Ventilation (NIV): CPAP or BiPAP might be attempted before intubation in selected cases.
   • Intubation and Mechanical Ventilation: For severe respiratory failure.
   • Consideration of specific antivirals (Ribavirin): Extremely rare, only for severely immunocompromised patients and life-threatening illness in consultation with specialists.

Complications

• Common:
  • Dehydration: Due to decreased oral intake and increased insensible fluid losses from tachypnea.
  • Otitis Media (OM): Acute otitis media is a common secondary bacterial infection, occurring in 20-30% of cases, often due to S. pneumoniae or H. influenzae.
  • Apnea: Especially in infants <2-3 months of age, premature infants, and those with underlying neurological conditions. Can be recurrent.
• Serious:
  • Respiratory Failure: Requiring mechanical ventilation.
  • Hypoxemia: Persistent low oxygen saturation.
  • Secondary Bacterial Pneumonia: Can be difficult to differentiate from viral pneumonitis. Suspect if new fever, worsening clinical status, or new focal findings.
  • Acute Respiratory Distress Syndrome (ARDS): Rare but severe complication.
  • Myocarditis or Heart Failure: Extremely rare.
• Long-term:
  • Recurrent Wheezing/Asthma: Strong association between severe RSV bronchiolitis in infancy and the development of recurrent wheezing and asthma in later childhood. This link is complex and likely involves both host predisposition and viral-induced airway remodeling.
  • Bronchiolitis Obliterans: A rare, severe, and irreversible obstructive lung disease that can follow adenovirus or RSV infection, characterized by inflammation and fibrosis of the small airways.

Prognosis

• Factors:
  • Age: Younger age (especially <6 months) is a significant risk factor for severe disease and hospitalization.
  • Underlying Medical Conditions: Prematurity, chronic lung disease, congenital heart disease, immunodeficiency, and neuromuscular disorders are associated with increased severity, hospitalization rates, and adverse outcomes.
  • Severity of Acute Illness: Initial oxygen requirements, need for ventilatory support, and length of hospital stay correlate with short-term morbidity.
  • Co-infections: Concurrent infections can worsen prognosis.
• Survival: The vast majority of otherwise healthy children recover completely from RSV infection. Mortality rates are very low in developed countries (<0.1% of hospitalized cases), but higher in infants with significant comorbidities (e.g., <5% in infants with CLD or severe CHD).
• Quality of Life: Most children return to baseline health. However, as noted, a significant percentage of those hospitalized with RSV bronchiolitis may experience recurrent wheezing or develop asthma, which can impact quality of life over time.

Prevention

Preventive strategies focus on reducing transmission and providing passive immunity to high-risk infants.

• Primary Prevention (Preventing initial occurrence):

  • Infection Control:
    • Hand Hygiene: Frequent and thorough handwashing with soap and water or alcohol-based hand sanitizer.
    • Avoidance of Sick Contacts: Limiting exposure of infants, especially high-risk ones, to individuals with respiratory symptoms.
    • Exclusion: Children and staff with respiratory symptoms should be excluded from childcare settings.
    • Environmental Cleaning: Regular cleaning and disinfection of surfaces.
    • Droplet Precautions: In healthcare settings, use of gowns, gloves, and masks.
  • Monoclonal Antibody Prophylaxis:
    • Nirsevimab (Beyfortus): A long-acting monoclonal antibody recommended for all infants <8 months of age born during or entering their first RSV season, and for infants 8-19 months of age who are at increased risk for severe RSV disease (e.g., CLD, severe immunocompromise) entering their second RSV season.
      • Dosing: Single intramuscular (IM) dose.
        • 50 mg for infants <5 kg
        • 100 mg for infants ≥5 kg
      • Administer shortly before or early in the RSV season.
    • Palivizumab (Synagis): A shorter-acting monoclonal antibody, administered monthly. Its use has significantly decreased with the advent of Nirsevimab. It is now primarily reserved for specific high-risk infants for whom Nirsevimab is not available or suitable (e.g., very specific populations where the duration of protection from Nirsevimab may be insufficient).
      • Dosing: 15 mg/kg IM once monthly, for a maximum of 5 doses during the RSV season.
      • Indications (historical/limited current use given Nirsevimab availability):
        • Infants born at ≤28 weeks, 6 days gestational age, during their first RSV season (if <12 months old at start of season).
        • Infants with CLD (BPD) requiring medical support (supplemental oxygen, bronchodilators, diuretics, or steroids) within 6 months before the start of the RSV season, if <12 months old at the start of season. Some guidelines extended to <24 months if still on therapy.
        • Infants with hemodynamically significant CHD, if <12 months old at the start of season.
        • Severe immunodeficiency (e.g., SCID, hematopoietic stem cell transplant recipients) if <24 months old.
        • Other conditions (e.g., specific neuromuscular conditions, cystic fibrosis with significant lung involvement) on a case-by-case basis.
  • Maternal RSV Vaccine (Abrysvo): A maternal vaccine administered in late pregnancy (typically 32-36 weeks gestation) to provide passive immunity to the infant via transplacental transfer of antibodies. Approved for use during the RSV season to protect infants from birth through 6 months of age.
    • Note: The CDC recommends either maternal RSV vaccination or infant nirsevimab for most infants to prevent severe RSV disease, but not both concurrently for most infants (consult latest ACIP guidelines for specific nuanced recommendations).

• Secondary Prevention: Early recognition of symptoms and prompt medical attention can help prevent progression to severe disease, especially in high-risk infants. No specific secondary interventions are available once infection is established.

• Tertiary Prevention: Management of complications (e.g., treating otitis media, managing respiratory failure) to minimize long-term sequelae.

Special Populations

• Pediatric: The primary focus of this reference. Infants <6 months, premature infants, and those with underlying heart or lung disease are at highest risk for severe disease.
• Geriatric: RSV can cause severe respiratory illness (bronchiolitis, pneumonia, exacerbation of COPD or CHF) in older adults, especially those with underlying cardiopulmonary disease or immunodeficiency. Two RSV vaccines are now approved for adults >60 years (Arexvy, Abrysvo).
• Pregnancy: RSV infection in pregnant individuals is usually mild (cold-like symptoms). The main concern is maternal vaccination for passive antibody transfer to the infant (as discussed in prevention).
• Comorbidities:
  • Chronic Lung Disease (CLD/BPD): Infants with CLD/BPD are at very high risk for severe RSV, prolonged hospitalization, and increased mortality. Prophylaxis with nirsevimab is highly recommended. Management involves aggressive supportive care, and they may require longer periods of oxygen or ventilatory support.
  • Congenital Heart Disease (CHD): Infants with hemodynamically significant CHD are at increased risk for severe RSV, particularly if they have pulmonary hypertension or congestive heart failure. Prophylaxis is recommended. RSV can exacerbate heart failure.
  • Immunocompromised: Children with primary or secondary immunodeficiencies are at high risk for severe, prolonged, and atypical RSV infections. Ribavirin may be considered in very severe cases in this population, but requires careful risk-benefit assessment.
  • Neuromuscular Disorders: Impaired cough reflex and airway clearance put these children at high risk for severe RSV and complications like aspiration. They may benefit from assisted airway clearance techniques.

Clinical Pearls

• Diagnostic:
  • Clinical Diagnosis First: In typical presentations, RSV bronchiolitis is a clinical diagnosis. Laboratory confirmation is often not necessary for management in otherwise healthy children.
  • Pulse Oximetry is Crucial: It is the most important objective measure for assessing severity and guiding management in acute bronchiolitis.
  • Beware of Apnea: Especially in young infants and premature babies, apnea can be the sole presenting symptom of RSV.
• Treatment:
  • Supportive Care is King: Resist the urge to use ineffective therapies like bronchodilators, steroids, or antibiotics routinely. They don't shorten illness or prevent hospitalization in most cases and can cause side effects.
  • Nasal Suctioning is Key: Simple nasal saline and suctioning can dramatically improve comfort, feeding, and breathing. Educate parents on proper technique.
  • Hydration, Hydration, Hydration: Poor feeding and increased respiratory effort lead to dehydration. Aggressive fluid management (oral, NG, or IV) is critical.
  • High-Flow Nasal Cannula (HFNC): A valuable tool for moderate-severe RSV bronchiolitis, often helping to avoid the need for mechanical ventilation.
• Pitfalls:
  • Over-reliance on CXR: Do not routinely order chest x-rays unless specific clinical concerns warrant it (e.g., suspicion of bacterial pneumonia, foreign body, significant worsening).
  • Routine Bronchodilator/Steroid Use: This is a common pitfall that does not improve outcomes and adds unnecessary cost and potential side effects.
  • Antibiotic Overuse: Only use antibiotics if there is clear evidence of a bacterial co-infection.
  • Sending Home Unstable Infants: Ensure careful assessment of SpO2, work of breathing, and feeding before discharge, especially for infants <3 months or those with risk factors. Apnea monitoring may be warranted for some.

Recent Updates

• Monoclonal Antibodies: The most significant recent update is the widespread availability and recommendation for Nirsevimab (Beyfortus).
  • Approved by FDA and recommended by ACIP in 2023 for all infants <8 months of age and select older high-risk infants for a single dose of protection. This marks a major shift from the more limited, multi-dose palivizumab strategy.
• Maternal RSV Vaccine: Abrysvo (Pfizer) was approved by the FDA in 2023 for use in pregnant individuals (32-36 weeks gestation) to protect infants from birth through 6 months of age. This offers another powerful tool for primary prevention.
• Guidelines: Recent updates to AAP (American Academy of Pediatrics) and CDC guidelines reflect the incorporation of nirsevimab and maternal vaccination into RSV prevention strategies. The focus remains strongly on supportive care for acute bronchiolitis.
• Evidence: Ongoing research continues to refine understanding of RSV pathogenesis, long-term sequelae, and the efficacy of various preventative agents. The clinical trials for nirsevimab and maternal RSV vaccines demonstrated significant reductions in medically attended RSV-associated lower respiratory tract illness and hospitalizations.
• Controversies:
  • Optimal Duration of Prophylaxis: While Nirsevimab offers a full season of protection, there is ongoing discussion about its cost-effectiveness and implementation strategies, particularly in years with prolonged RSV seasons.
  • Bronchodilator/Steroid Use: Despite strong evidence against routine use, these therapies are still frequently prescribed. Ongoing efforts aim to de-implement these ineffective practices.
  • RSV-Asthma Link: The precise mechanisms underlying the association between severe RSV in infancy and later asthma remain an area of active research.

Key References

• Guidelines:
  • American Academy of Pediatrics (AAP) Clinical Practice Guideline: Bronchiolitis: Diagnosis and Management of Bronchiolitis in Infants and Young Children. Updated periodically (most recently 2014, with subsequent policy statements on prophylaxis).
  • Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP): Recommendations for Immunization with Nirsevimab and Maternal RSV Vaccine. These are the most current and authoritative guidelines for RSV prophylaxis.
  • National Institute for Health and Care Excellence (NICE) Guideline: Bronchiolitis in children: diagnosis and management. (UK-based, regularly updated).
• Studies:
  • Nirsevimab Clinical Trials (MELODY, HARMONY): Landmark studies demonstrating the efficacy and safety of nirsevimab for RSV prevention in infants.
  • Palivizumab Clinical Trials (IMpact-RSV): Historical trials demonstrating efficacy of palivizumab in high-risk infants.
• Reviews:
  • UpToDate: "Respiratory syncytial virus infection: Clinical features and diagnosis in infants and children" and "Respiratory syncytial virus infection: Management in infants and children."
  • Cochrane Reviews: Multiple systematic reviews assessing the efficacy of various interventions (e.g., bronchodilators, corticosteroids) for bronchiolitis.